Delta-like 3 (Drosophila), also known as DLL3, is a protein which in humans is encoded by the DLL3 gene. [5] Two transcript variants encoding distinct isoforms have been identified for this gene.

Nov 19, 2024 · Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) …

DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the …

May 27, 2025 · Delta-like ligand 3 (DLL3) serves as a therapeutic target in solid tumors, particularly in neuroendocrine cancers, where its expression is linked to aggressive tumor behavior and poor …

Nov 13, 2025 · DLL3 (Delta Like Canonical Notch Ligand 3) is a Protein Coding gene. Diseases associated with DLL3 include Spondylocostal Dysostosis 1, Autosomal Recessive and …

Nov 1, 2023 · Delta-like ligand 3 (DLL3) regulates the proliferation, metastasis and invasion of SCLC cells. DLL3 is overexpressed on the surface of SCLC cells. Rova-T, AMG119 and AMG757 are DLL3 …

Apr 29, 2025 · Delta-like ligand 3 (DLL3) has gained attention for its role in small cell lung cancer (SCLC), a highly aggressive malignancy with limited treatment options. Unlike other Notch ligands, …

May 10, 2024 · These findings indicate that the value of DLL3 expression as a predictive biomarker is still limited. Further studies are warranted to define biomarkers that predict DLL3-targeting treatment …

Apr 16, 2025 · Delta-like 3 (DLL3) is an oncogenic protein aberrantly expressed in several tumors, particularly in small-cell lung cancer. DLL3-targeted therapies have recently made significant …

Feb 16, 2025 · DLL3, a ligand in the Notch signaling pathway, is estimated to be expressed on the cell surface of 80% of SCLC cells, highlighting it as a potential therapeutic target.